Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE), has updated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results